1st Quarter - Report
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to Medicare coverage of compounded medications
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON RAFAEL LOPEZ New | — |
| AMY SHANK | — |
Health Issues HCR
TriCare benefit issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON RAFAEL LOPEZ New | — |
| AMY SHANK | — |
Pharmacy PHA
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON RAFAEL LOPEZ New | — |
| AMY SHANK | — |
Budget/Appropriations BUD
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON RAFAEL LOPEZ New | — |
| AMY SHANK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.